Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat.

OBJECTIVE In electrically remodeled atria the effect of blockers of the delayed rectifier K+ current I(Kr) on repolarization is reduced, whereas the efficacy of 'early' class III drugs (I(Kur)/I(to)/I(Kach) blockers) is enhanced. We evaluated the electrophysiological and antifibrillatory effects of AVE0118, dofetilide, and ibutilide (alone and in combination) on persistent atrial fibrillation (AF) in the goat. METHODS AND RESULTS The effects of separate and combined administration of AVE0118, dofetilide, and ibutilide were determined before and after 48 h of AF. AVE0118 alone markedly prolonged the atrial refractory period (400 ms cycle length) (AERP400) before and after 48 h of AF. The prolongation of AERP(400) by dofetilide and ibutilide, respectively, was reduced by AF from 22+/-2 to 7+/-2 ms (p<0.01) and 25+/-5 to 5+/-2 ms (p=0.01). Pre-treatment with AVE0118 restored the prolongation of AERP400 by dofetilide or ibutilide (to 20+/-3 and 30+/-6 ms; p<0.01). This effect was atrial specific since the QT-interval was not changed. The antifibrillatory action was evaluated in 10 goats that were in persistent AF for 57+/-7 days. Dofetilide (20 microg/kg/h) or ibutilide (4 mg/h) alone restored sinus rhythm in only 20% of the animals. AVE0118 (1, 3 and 10 mg/kg/h) [DOSAGE ERROR CORRECTED] terminated AF in 11, 30, and 60%, respectively. Additional infusion of I(Kr) blockers caused an additional number of cardioversions, resulting in a final cardioversion rate of 56, 80, and 100%, respectively. AVE0118 alone prolonged the AF cycle length (AFCL) while the conduction velocity during AF (CV(AF)) remained unchanged (70+/-1 vs. 68+/-2 cm/s; p=0.3). Addition of dofetilide or ibutilide caused a synergistic increase in AFCL and a slight increase in CV(AF) to 74+/-1 cm/s (p<0.001). The length of the reentrant trajectories increased from 7.6+/-0.3 (control) to 11.6+/-0.5 cm after AVE0118 alone (p<0.001) and 14.8+/-0.8 cm after addition of dofetilide or ibutilide (p<0.001). CONCLUSIONS In electrically remodeled atria, blockade of I(Kur)/I(to)/I(KAch) restored the class III action of I(Kr) blockers. Persistent AF could be effectively cardioverted by infusion of a combination of AVE0118 and dofetilide or ibutilide. This antifibrillatory action was associated with an almost twofold lengthening of the intra-atrial pathways for reentry.

[1]  S Nattel,et al.  Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. , 1996, Circulation research.

[2]  K. Ellenbogen,et al.  Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. , 1996, Circulation.

[3]  P. Kowey,et al.  Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. , 1998, Journal of the American College of Cardiology.

[4]  D. Roden,et al.  Quinidine delays IK activation in guinea pig ventricular myocytes. , 1988, Circulation research.

[5]  Mark A. Wood,et al.  Efficacy and Safety of Repeated Intravenous Doses of Ibutilide for Rapid Conversion of Atrial Flutter or Fibrillation , 1996 .

[6]  Bertram Pitt,et al.  Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction , 1996, The Lancet.

[7]  U Schotten,et al.  “Early” Class III Drugs for the Treatment of Atrial Fibrillation: Efficacy and Atrial Selectivity of AVE0118 in Remodeled Atria of the Goat , 2004, Circulation.

[8]  S Nattel,et al.  Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. , 1997, Circulation research.

[9]  I. V. Van Gelder,et al.  Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. , 2006, Heart rhythm.

[10]  M. Allessie,et al.  Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs. , 2005, Cardiovascular research.

[11]  J. Nerbonne Molecular basis of functional voltage‐gated K+ channel diversity in the mammalian myocardium , 2000, The Journal of physiology.

[12]  K. Stangl,et al.  Superiority of ibutilide (a new class III agent) overdl-sotalol in converting atrial flutter and atrial fibrillation , 1998, Heart.

[13]  M. Allessie,et al.  Widening of the excitable gap during pharmacological cardioversion of atrial fibrillation in the goat: effects of cibenzoline, hydroquinidine, flecainide, and d-sotalol. , 2000, Circulation.

[14]  S. Nattel,et al.  Cardiac Ultrarapid Delayed Rectifiers , 1999, Cellular Physiology and Biochemistry.

[15]  A. Waldo,et al.  Azd7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. , 2004, Journal of cardiovascular electrophysiology.

[16]  I. Stiell,et al.  A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. , 2004, Journal of the American College of Cardiology.

[17]  R. Sah,et al.  Targeted expression of a dominant-negative K(v)4.2 K(+) channel subunit in the mouse heart. , 1999, Circulation research.

[18]  M. Allessie,et al.  Automatic mapping of human atrial fibrillation by template matching. , 2006, Heart rhythm.

[19]  J. L. Kenyon,et al.  4-Aminopyridine and the early outward current of sheep cardiac Purkinje fibers , 1979, The Journal of general physiology.

[20]  C. Lau,et al.  Electrophysiologic actions of dl-sotalol in patients with persistent atrial fibrillation. , 2002, Journal of the American College of Cardiology.

[21]  D. Dobrev,et al.  Role of IKur in Controlling Action Potential Shape and Contractility in the Human Atrium: Influence of Chronic Atrial Fibrillation , 2004, Circulation.

[22]  P. Volders,et al.  Atrial-specific drug AVE0118 is free of torsades de pointes in anesthetized dogs with chronic complete atrioventricular block. , 2006, Heart rhythm.

[23]  D. Fedida,et al.  The Mechanism of Atrial Antiarrhythmic Action of RSD1235 , 2005, Journal of cardiovascular electrophysiology.

[24]  S Nattel,et al.  Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. , 1999, Cardiovascular research.

[25]  M. Bleich,et al.  Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[26]  M. Allessie,et al.  Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. , 1995, Circulation.